Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)

Blood. 2007 Nov 15;110(10):3526-31. doi: 10.1182/blood-2007-01-065763. Epub 2007 Aug 13.

Abstract

Patients with severe immune thrombocytopenic purpura (ITP) may require an acute increase in the platelet count for surgery or ongoing hemorrhage as well as long-term maintenance treatment. Certain of these patients may be refractory to steroids, intravenous anti-D, intravenous immunoglobulin (IVIG), and splenectomy. Therefore, acute platelet increases were studied in 35 patients completely unresponsive to IVIG or high-dose steroid treatment. Because of their lack of response to either or both single agents, these patients were administered a 3- or 4-drug combination including IVIG 1 g/kg, intravenous methylprednisolone 30 mg/kg, Vinca alkaloids (VCR 0.03 mg/kg), and/or intravenous anti-D (50-75 microg/kg). Subsequent maintenance therapy with the oral combination of danazol (10-15 mg/kg) and azathioprine (2 mg/kg) was given to 18 of the 35 patients. Seventy-one percent of the patients responded to the intravenous combination treatment with acute platelet increases of at least 20 x 10(9)/L to a level greater than 30 x 10(9)/L. Two thirds of the patients given maintenance therapy achieved stable platelet counts greater than 50 x 10(9)/L without other treatments. One patient developed an ileus, but otherwise there was little toxicity of combination treatment. Combination chemotherapy is a useful approach for patients with ITP refractory to conventional treatments both for acute induction and for long-term maintenance therapy.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / administration & dosage
  • Azathioprine / administration & dosage*
  • Child
  • Child, Preschool
  • Danazol / administration & dosage*
  • Drug Administration Routes
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Immunosuppressive Agents / administration & dosage
  • Male
  • Methylprednisolone / administration & dosage*
  • Middle Aged
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Time Factors
  • Treatment Failure

Substances

  • Anti-Inflammatory Agents
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Azathioprine
  • Danazol
  • Methylprednisolone